Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.
暂无分享，去创建一个
R. Yelensky | A. Tinker | A. Oza | J. Brenton | C. Scott | E. Swisher | I. McNeish | R. Coleman | A. Leary | G. Konecny | S. Goble | M. Raponi | R. Kristeleit | K. Bell-McGuinn | A. Oaknin | D. O’Malley | L. Rolfe | A. Allen | H. Giordano | K. Lin